IQVIA艾昆纬：2024年在新的投资环境中管理新兴的生物制药运营成本白皮书（英文版）

In Part 2 of our analysis, we shifted our focus to EBP products launched as new chemical entities (NCEs) and Biologics License Applications (BLAs). And, while we have applied the same methodology to measure financial success, we expanded our scope to also incorporate insights into the commercial strategies behind the finances of these products. Between 2012-2023, analysis of 34 EBP launches revealed the critical role of a product’s clinical differentiation on its commercial strategy and deplo